Fifty-three cancer researchers from eight different academic institutions around the country and their federal agency partners met in Chapel Hill on January 27 and 28 to launch the next five years of the Cancer Prevention and Control Research Network (CPCRN). In September 2019, the Division of Cancer Prevention and Control at the Centers for Disease Control and Prevention (CDC) awarded the NYU Grossman School of Medicine and the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) $1.5 million over the next five years to participate in the network as one of its eight collaborating centers.
For the 2019-2024 cycle of funding, the New York City (NYC) CPCRN is one of two new CPCRN collaborating centers. Six centers will rejoin or continue to participate in the network with renewed funding. The centers and their principal investigators are as follows: Emory University: Cam Escoffery, PhD University of Iowa: Natoshia Askelson, PhD NYU Grossman School of Medicine-City University of New York : Chau Trinh-Shevrin, DrPH University of Arizona: Cynthia Thomson, PhD University of South Carolina at Columbia: Daniela Friedman, PhD and James R Hébert, ScD Colorado School of Public Health: Betsy Risendal, PhD University of North Carolina - Chapel Hill: Jennifer Leeman, DrPH, MDiv and Alison Brenner, PhD University of Washington: Peggy Hannon, PhD and Linda Ko, PhD CPCRN Coordinating Center: Stephanie Wheeler, PhD
Initiated in 2002, CPCRN is the largest and longest-standing thematic research network of the Prevention Research Center (PRC) program, the CDC's flagship program for preventing and controlling chronic diseases. Eight PRCs from around the country participate in CPCRN, including the NYC PRC. Researchers from each PRC collaborate within and across their centers to produce research related to the implementation of evidence-based approaches to reduce the burden of cancer, especially in disproportionately affected populations. Since 2004, CPCRN members have produced 1,796 publications and obtained over $669 million in grant funding.
We are delighted to be in our 16th year of continuous funding as the Coordinating Center for the CDC Prevention Research Centers' largest thematic research network. CPCRN has made a profound impact on the science and practice of cancer prevention and control research translation over the years, and we are excited about the new and returning centers that are part of the network in this current cycle." Stephanie Wheeler, the principal investigator for the CPCRN Coordinating Center
Over the next five years, CPCRN researchers will contribute to cross-center projects to extend research findings across the cancer control continuum into practice. At this week's meeting, researchers developed consensus around potential thematic areas for the projects, to be coordinated by cross-center workgroups. The proposed areas of focus include cancer survivorship; cancer among rural populations; organization theory in implementation science; applied systems science; a CPCRN scholars trainee program; implementation, quality improvement, and technical assistance; health behaviors; health equity and social determinants of health; and mental health and well-being.
Each center will also complete a five-year center project that will study the implementation of cancer control interventions directed at one or more levels of the health care context, which may include the patient, a health system, a community, or a wider political or economic context that impacts health outcomes. "The NYC CPCRN harnesses the strengths of an established public-private partnership between CUNY SPH and NYU Grossman School of Medicine to reduce preventable cancer disparities among minority and immigrant populations in NYC through community-engaged implementation science and population health approaches," said Chau Trinh-Shevrin, DrPH, principal investigator for the NYC CPCRN, Associate Professor in the Departments of Population Health and Medicine, NYU Grossman School of Medicine, and the Associate Director of Community Outreach and Engagement for NYU Langone's Perlmutter Cancer Center. Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology